Heartflow (NASDAQ:HTFL) Price Target Raised to $40.00 at JPMorgan Chase & Co.

Heartflow (NASDAQ:HTFL) had its target price lifted by analysts at JPMorgan Chase & Co. from $36.00 to $40.00 in a report released on Thursday,Benzinga reports. The firm presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective would indicate a potential upside of 27.27% from the stock’s previous close.

Other equities research analysts have also issued reports about the stock. Weiss Ratings began coverage on shares of Heartflow in a research report on Saturday, November 1st. They set a “sell (d+)” rating on the stock. Stifel Nicolaus boosted their price objective on shares of Heartflow from $35.00 to $40.00 and gave the stock a “buy” rating in a report on Thursday. Zacks Research raised shares of Heartflow to a “hold” rating in a report on Wednesday, September 3rd. Piper Sandler started coverage on shares of Heartflow in a research report on Tuesday, September 2nd. They set an “overweight” rating and a $38.00 price target for the company. Finally, Morgan Stanley started coverage on Heartflow in a report on Tuesday, September 2nd. They issued an “equal weight” rating and a $35.00 price target on the stock. Four analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $38.40.

Heartflow Trading Down 12.1%

NASDAQ HTFL traded down $4.31 on Thursday, hitting $31.43. 976,027 shares of the company’s stock were exchanged, compared to its average volume of 417,297. The firm has a 50-day moving average price of $34.73. Heartflow has a fifty-two week low of $26.56 and a fifty-two week high of $41.22.

Heartflow (NASDAQ:HTFL) last posted its quarterly earnings results on Friday, September 19th. The company reported ($1.46) EPS for the quarter, missing the consensus estimate of ($0.20) by ($1.26). The firm had revenue of $43.42 million during the quarter, compared to analyst estimates of $43.20 million.

Hedge Funds Weigh In On Heartflow

Several large investors have recently added to or reduced their stakes in HTFL. TFC Financial Management Inc. acquired a new stake in Heartflow during the third quarter worth $40,000. Legal & General Group Plc acquired a new position in shares of Heartflow in the 3rd quarter worth approximately $59,000. Y Intercept Hong Kong Ltd acquired a new position in Heartflow in the third quarter worth $234,000. Legato Capital Management LLC bought a new position in shares of Heartflow in the third quarter valued at about $243,000. Finally, TrueMark Investments LLC bought a new position in shares of Heartflow in the third quarter worth about $918,000.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.